These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 29708513)

  • 1. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.
    Yu J; Qin B; Moyer AM; Nowsheen S; Liu T; Qin S; Zhuang Y; Liu D; Lu SW; Kalari KR; Visscher DW; Copland JA; McLaughlin SA; Moreno-Aspitia A; Northfelt DW; Gray RJ; Lou Z; Suman VJ; Weinshilboum R; Boughey JC; Goetz MP; Wang L
    J Clin Invest; 2018 Jun; 128(6):2376-2388. PubMed ID: 29708513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting DNA methylation for treating triple-negative breast cancer.
    Yu J; Zayas J; Qin B; Wang L
    Pharmacogenomics; 2019 Nov; 20(16):1151-1157. PubMed ID: 31755366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.
    Kastl L; Brown I; Schofield AC
    Int J Oncol; 2010 May; 36(5):1235-41. PubMed ID: 20372798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.
    Billam M; Sobolewski MD; Davidson NE
    Breast Cancer Res Treat; 2010 Apr; 120(3):581-92. PubMed ID: 19459041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer.
    Kala R; Shah HN; Martin SL; Tollefsbol TO
    BMC Cancer; 2015 Oct; 15():672. PubMed ID: 26459286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decitabine Response in Breast Cancer Requires Efficient Drug Processing and Is Not Limited by Multidrug Resistance.
    Dahn ML; Cruickshank BM; Jackson AJ; Dean C; Holloway RW; Hall SR; Coyle KM; Maillet H; Waisman DM; Goralski KB; Giacomantonio CA; Weaver ICG; Marcato P
    Mol Cancer Ther; 2020 May; 19(5):1110-1122. PubMed ID: 32156786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of DNMT1 and ERRα crosstalk suppresses breast cancer via derepression of IRF4.
    Vernier M; McGuirk S; Dufour CR; Wan L; Audet-Walsh E; St-Pierre J; Giguère V
    Oncogene; 2020 Oct; 39(41):6406-6420. PubMed ID: 32855526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The frequency of CpG and non-CpG methylation of Notch3 gene promoter determines its expression levels in breast cancer cells.
    Xiao W; Liu X; Niu X; Li C; Guo Y; Tan J; Xiong W; Fan L; Li Y
    Exp Cell Res; 2020 Jan; 386(2):111743. PubMed ID: 31770532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant methylation accounts for cell adhesion-related gene silencing during 3-methylcholanthrene and diethylnitrosamine induced multistep rat lung carcinogenesis associated with overexpression of DNA methyltransferases 1 and 3a.
    Liu WB; Cui ZH; Ao L; Zhou ZY; Zhou YH; Yuan XY; Xiang YL; Liu JY; Cao J
    Toxicol Appl Pharmacol; 2011 Feb; 251(1):70-8. PubMed ID: 21163286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eugenol modulates genomic methylation and inactivates breast cancer-associated fibroblasts through E2F1-dependent downregulation of DNMT1/DNMT3A.
    Al-Kharashi LA; Bakheet T; AlHarbi WA; Al-Moghrabi N; Aboussekhra A
    Mol Carcinog; 2021 Nov; 60(11):784-795. PubMed ID: 34473867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells.
    Yan F; Shen N; Pang J; Molina JR; Yang P; Liu S
    J Biol Chem; 2015 Jul; 290(30):18480-94. PubMed ID: 26085088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kaempferol Modulates DNA Methylation and Downregulates DNMT3B in Bladder Cancer.
    Qiu W; Lin J; Zhu Y; Zhang J; Zeng L; Su M; Tian Y
    Cell Physiol Biochem; 2017; 41(4):1325-1335. PubMed ID: 28278502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-155 increases stemness and decitabine resistance in triple-negative breast cancer cells by inhibiting TSPAN5.
    Yang LW; Wu XJ; Liang Y; Ye GQ; Che YC; Wu XZ; Zhu XJ; Fan HL; Fan XP; Xu JF
    Mol Carcinog; 2020 Apr; 59(4):447-461. PubMed ID: 32096299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
    Buocikova V; Longhin EM; Pilalis E; Mastrokalou C; Miklikova S; Cihova M; Poturnayova A; Mackova K; Babelova A; Trnkova L; El Yamani N; Zheng C; Rios-Mondragon I; Labudova M; Csaderova L; Kuracinova KM; Makovicky P; Kucerova L; Matuskova M; Cimpan MR; Dusinska M; Babal P; Chatziioannou A; Gabelova A; Rundén-Pran E; Smolkova B
    Biomed Pharmacother; 2022 Mar; 147():112662. PubMed ID: 35091237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity.
    Kim HJ; Kim JH; Chie EK; Young PD; Kim IA; Kim IH
    Radiat Oncol; 2012 Mar; 7():39. PubMed ID: 22429326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-aza-2'-Deoxycytidine, a DNA methyltransferase inhibitor, facilitates the inorganic phosphorus-induced mineralization of vascular smooth muscle cells.
    Azechi T; Sato F; Sudo R; Wachi H
    J Atheroscler Thromb; 2014; 21(5):463-76. PubMed ID: 24441913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cancer-testis gene,
    Gu Y; Wang C; Zhu R; Yang J; Yuan W; Zhu Y; Zhou Y; Qin N; Shen H; Ma H; Wang H; Liu X; Hu Z
    Cancer Biol Med; 2021 Feb; 18(1):74-87. PubMed ID: 33628586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNMT1: A key drug target in triple-negative breast cancer.
    Wong KK
    Semin Cancer Biol; 2021 Jul; 72():198-213. PubMed ID: 32461152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
    Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
    Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.